Eli Lilly and Novo are developing amylin-targeting drugs to complement GLP-1 obesity medications. Lilly's eloralintide combined with tirzepatide produced 23.3% average weight loss in a Phase 2 trial, substantially more than tirzepatide alone, potentially offering new options for the millions who don't respond adequately to existing GLP-1 drugs.
Eli Lilly and Novo are developing amylin-targeting drugs to complement GLP-1 obesity medicines. Lilly's eloralintide combined with tirzepatide showed 23.3% weight loss versus 14.8% with tirzepatide alone in Phase 2 trials, with potential annual sales forecasted at $23.2 billion by 2035. The approach targets millions of patients who don't respond adequately to existing GLP-1 drugs, though tolerability concerns remain.
Eli Lilly reported that its combination treatment eloraTZP, combining an amylin receptor agonist with Zepbound, achieved 23.3% average weight loss in patients with obesity/overweight and type 2 diabetes, outperforming its triple-G candidate retatrutide in this population. At the highest dose, patients lost an average of 54.1 pounds over 48 weeks with improved blood sugar control, though gastrointestinal adverse events led to discontinuation in up to 27% of patients. Lilly plans to initiate phase 3 trials in late 2026.
Eli Lilly announced that its experimental combination of eloralintide and tirzepatide produced greater weight loss (23.3%) than tirzepatide alone (14.8%) in a Phase 2 trial for obesity and Type 2 diabetes patients. The combo therapy met primary endpoints and plans to advance to Phase 3 trials, though discontinuation rates due to gastrointestinal side effects were higher in the combination group.